Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Xi, Dong ^a   Wang, Ming ^a   Ye, Huali ^a   Luo, Xiaoping ^a   Ning, Qin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; CYTOKINE; FAS ANTIGEN; FIBRINOGEN LIKE PROTEIN 2; MICRORNA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CHO CELL; CONTROLLED STUDY; FEMALE; FIBRIN DEPOSITION; FULMINANT HEPATIC FAILURE; GENE EXPRESSION; INFLAMMATORY INFILTRATE; LIVER NECROSIS; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; SURVIVAL RATE; SURVIVAL TIME;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CASPASE 3; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; FIBRIN; FIBRINOGEN; GENE EXPRESSION REGULATION; GENETIC VECTORS; LIVER; LIVER FAILURE, ACUTE; MICE; MICRORNAS; PLASMIDS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA INTERFERENCE;

EID: 84896700072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082330     Document Type: Article

References (46)

1. Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337: 1733-1745. doi:10.1056/NEJM199712113372406. PubMed: 9392700.
2. Pawlotsky JM (2002) Molecular diagnosis of viral hepatitis. Gastroenterology 122: 1554-1568. doi:10.1053/gast.2002.33428. PubMed: 12016423.
3. Cheng VC, Lo CM, Lau GK (2003) Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. Semin Liver Dis 23: 239-250. doi:10.1055/s-2003-42642. PubMed: 14523677.
4. Ke WM, Ye YN, Huang S (2003) Discriminant function for prognostic indexes and probability of death in chronic severe hepatitis B. J Gastroenterol 38: 861-864. doi:10.1007/s00535-003-1162-3. PubMed: 14564632.
5. Zou Y, Chen T, Han M, Wang H, Yan W et al. (2010) Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol 184: 466-475. doi:10.4049/jimmunol.0900687. PubMed: 19949088.
6. Stravitz RT, Kramer DJ (2009) Management of acute liver failure. Nat Rev Gastroenterol Hepatol 6: 542-553. doi:10.1038/nrgastro.2009.127. PubMed: 19652652.
7. Coleman WB (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3: 573-588. doi:10.2174/1566524033479546. PubMed: 14527088.
8. Nakamoto Y, Kaneko S (2003) Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 3: 537-544. doi:10.2174/1566524033479591. PubMed: 14527085.
9. Marsden PA, Ning Q, Fung LS, Luo X, Chen Y et al. (2003) The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 112: 58-66. doi:10.1172/JCI200318114. PubMed: 12840059.
10. Zhu C, Sun Y, Luo X, Yan W, Xi D et al. (2006) Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Hum Gene Ther 17: 589-600. doi:10.1089/hum.2006.17.589. PubMed: 16776568.
11. Armbrust T, Kreissig M, Tron K, Ramadori G (2004) Modulation of fibronectin gene expression in inflammatory mononuclear phagocytes of rat liver after acute liver injury. J Hepatol 40: 638-645. doi:10.1016/j.jhep.2003.12.013. PubMed: 15030980.
12. Zhu CL, Yan WM, Zhu F, Zhu YF, Xi D et al. (2005) Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J Gastroenterol 11: 6936-6940. PubMed: 16437596.
13. Song E, Lee SK, Wang J, Ince N, Ouyang N et al. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351. doi:10.1038/nm828. PubMed: 12579197.
14. Jiang N, Zhang X, Zheng X, Chen D, Siu K et al. (2012) A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis. PLOS ONE 7: e44138. doi:10.1371/journal.pone. 0044138. PubMed: 22970170.
15. Wullaert A, Wielockx B, Van Huffel S, Bogaert V, De Geest B et al. (2005) Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology 42: 381-389. doi:10.1002/hep. 20785. PubMed: 16025521.
16. Nakayama Y, Shimizu Y, Hirano K, Ebata K, Minemura M et al. (2005) CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis. Hepatology 42: 915-924. doi:10.1002/hep. 20872. PubMed: 16175605.
17. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854. doi:10.1016/0092-8674(93)90529-Y. PubMed: 8252621.
18. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. doi:10.1016/S0092-8674(04)00045-5. PubMed: 14744438.
19. O'Donnell JM, Kalichira A, Bi J, Lewandowski ED (2012) In vivo, cardiac-specific knockdown of a target protein, malic enzyme-1, in rat via adenoviral delivery of DNA for non-native miRNA. Curr Gene Ther 12: 454-462. doi:10.2174/156652312803519760. PubMed: 22974418.
20. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R et al. (1998) Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 160: 3487-3493. PubMed: 9531310.
21. Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430: 242-249. doi:10.1038/nature02759. PubMed: 15241422.
22. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576. doi:10.1053/j. gastro.2007.04.061. PubMed: 17570226.
23. Wu Z, Han M, Chen T, Yan W, Ning Q (2010) Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int 30: 782-794. doi:10.1111/j.1478- 3231.2010.02262.x. PubMed: 20492514.
24. Schwartz BS, Levy GA, Fair DS, Edgington TS (1982) Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase. J Exp Med 155: 1464-1479. doi:10.1084/jem.155.5.1464. PubMed: 7200121.
25. Levy GA, Liu M, Ding J, Yuwaraj S, Leibowitz J et al. (2000) Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 156: 1217-1225. doi:10.1016/S0002-9440(10)64992-9. PubMed: 10751347.
26. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST et al. (2009) Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 3: 269-282. doi:10.1007/s12072-008-9106-x. PubMed: 19669378.
27. Pinkoski MJ, Brunner T, Green DR, Lin T (2000) Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 278: G354-G366. PubMed: 10712254.
28. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809. doi:10.1038/364806a0. PubMed: 7689176.
29. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G et al. (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223-1230. doi:10.1084/jem.182.5.1223. PubMed: 7595193.
30. Rivero M, Crespo J, Fábrega E, Casafont F, Mayorga M et al. (2002) Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 9: 107-113. doi:10.1046/j.1365-2893.2002.00338.x. PubMed: 11876792.
31. Mita A, Hashikura Y, Tagawa Y, Nakayama J, Kawakubo M et al. (2005) Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol 100: 2551-2559. doi:10.1111/j.1572-0241. 2005.00265.x. PubMed: 16279913.
32. Malhi H, Gores GJ, Lemasters JJ (2006) Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43: S31-S44. doi:10.1002/hep.21062. PubMed: 16447272.
33. Ryo K, Kamogawa Y, Ikeda I, Yamauchi K, Yonehara S et al. (2000) Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 95: 2047-2055. doi:10.1111/j.1572-0241.2000.02268.x. PubMed: 10950056.
34. Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G et al. (1994) Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 153: 1778-1788. PubMed: 8046244.
35. Yoon S, Kim TH, Natarajan A, Wang SS, Choi J et al. (2010) Acute liver injury upregulates microRNA-491-5p in mice, and its overexpression sensitizes Hep G2 cells for tumour necrosis factor-alpha-induced apoptosis. Liver Int 30: 376-387. doi:10.1111/j. 1478-3231.2009.02181.x. PubMed: 20015148.
36. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K et al. (1993) Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467. doi:10.1016/0092-8674(93)90134-C. PubMed: 8387893.
37. Sekiyama KD, Yoshiba M, Thomson AW (1994) Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 98: 71-77. PubMed: 7923888.
38. Tokushige K, Yamaguchi N, Ikeda I, Hashimoto E, Yamauchi K et al. (2000) Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am J Gastroenterol 95: 2040-2046. doi:10.1111/j.1572-0241.2000.02270.x. PubMed: 10950055.
39. Gao S, Wang M, Ye H, Guo J, Xi D et al. (2010) Dual interference with novel genes mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Hum Gene Ther 21: 969-977. doi:10.1089/hum.2009.177. PubMed: 20218879.
40. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. doi:10.1038/35888. PubMed: 9486653.
41. Wilson JM (1996) Adenoviruses as gene-delivery vehicles. N Engl J Med 334: 1185-1187. doi:10.1056/NEJM199605023341809. PubMed: 8602187.
42. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL (1993) Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 4: 403-409. doi:10.1089/hum.1993.4.4-403. PubMed: 8399487.
43. Guo ZS, Wang LH, Eisensmith RC, Woo SL (1996) Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 3: 802-810. PubMed: 8875229.
44. Kuriyama S, Tominaga K, Kikukawa M, Tsujimoto T, Nakatani T et al. (1999) Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver. Gene Ther 6: 749-757. doi: 10.1038/sj.gt.3300894. PubMed: 10505097.
45. Wei RC, Cao X, Gui JH, Zhou XM, Zhong D et al. (2011) Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Hum Gene Ther 22: 1109-1119. doi:10.1089/hum.2010.219. PubMed: 21361790.
46. Liu XR, Cai Y, Cao X, Wei RC, Li HL et al. (2012) A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect. J Cell Mol Med 16: 1298-1309. doi:10.1111/j.1582-4934.2011.01396.x. PubMed: 21794078.